Neuroform Atlas® Stent System Granted an Expanded Indication

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Neuroform Atlas® Stent System by Stryker has received U.S. Food and Drug Administration (FDA) approval for an expanded indication becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation.

Aneurysms in the posterior circulation rupture more frequently and are generally more difficult to treat. With the approval of the Neuroform Atlas adjunctive stent for the posterior circulation, long term treatment is more feasible.

Already approved for use in the anterior circulation, the expanded indication was granted based on robust clinical trial evidence proving the safety and efficacy of the device.  The combined patients from both the anterior and posterior cohorts totaled 298 patients, making it the largest study of its kind.

“The Atlas Posterior PMA trial data shows a compelling advancement in the treatment of wide-neck posterior aneurysms,” said Dr. Sam Zaidat, Director of the Neuroscience and Stroke Center at Mercy Health System in Toledo, Ohio, and Co-Principal Investigator of the U.S. Neuroform Atlas investigational trial. “Posterior stent-assisted coiling with Neuroform Atlas achieved an impressive high rate of complete occlusion in this very challenging location at 76.7%. Equally impressive was the 4.3% primary safety rate.”

An estimated 6.5 million people in the United States have unruptured brain aneurysms with an average rupture rate of 1 every 18 minutes.  Ruptured brain aneurysms are fatal in roughly 50% of cases.1

“Complete occlusion, or complete blocking of blood flow, is the gold standard in determining long term aneurysm healing,” said Dr. Brian Jankowitz, Director, Cerebrovascular Surgery at the Cooper Neurological Institute in Camden, New Jersey.  “With the additional challenges that come with treating posterior circulation aneurysms, we never would have anticipated reaching occlusion rates that rival those found in the anterior circulation. Now with Neuroform Atlas, those same high rates are achievable.”

“The results from the Atlas Posterior PMA trial demonstrate that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population,” said Mark Paul, president of Stryker’s Neurovascular division. “This expanded indication of Neuroform Atlas, as the first and only adjunctive stent for use in the posterior circulation, reflects our ongoing commitment to advancing stroke care for patients with cerebrovascular disease.”

spot_img

DON'T MISS

Related Articles